Barclays Maintains Underweight on NOV, Lowers Price Target to $20

Benzinga Newsdesk www.benzinga.com Negative 92.5%

Neg 92.5% Neu 0% Pos 0%

Barclays analyst David Anderson maintains NOV (NYSE:NOV) with a Underweight and lowers the price target from $21 to $20.